The cardiac-myosin inhibitor developer priced one of the year’s larger biotech IPOs to fund BHB-1893, a would-be rival to Bristol Myers’ Camzyos for a serious heart-muscle disease.
In a 170-patient, placebo-controlled study, dronabinol cut nightmare severity more than placebo — though it did not clearly reduce overall PTSD or depression.
Cleared for adults 50 and older, the shot cut confirmed influenza by 27% versus a standard vaccine in 50-to-64-year-olds — a landmark for mRNA beyond COVID.
CEO Mike Doustdar says the obesity giant will stick to smaller ‘bolt-on’ deals after clinical setbacks and a Wegovy sales miss, amid intensifying pressure from Eli Lilly.
A large Nature study found that inflammation — not a weakened immune system — reactivates viruses like Epstein-Barr during severe COVID, and one viral family tracked with long COVID.
From a whole-genome map built on over a trillion lab-grown neurons, the partners pinpointed a novel neuro target in 15 months — the first payoff from a collaboration worth up to $12 billion.
The startup’s AI runs virtual versions of trials to predict patient responses and flag design flaws — aiming at the industry’s roughly 90% clinical-trial failure rate.
The Series B, led by General Atlantic, backs EXPD-101, a once-daily DPP1 inhibitor licensed from Fosun Pharma and now entering a global Phase 2 trial in COPD.
Kindred Companion Sciences edited a single gene to knock out Can f 1, the protein behind most dog allergies — and says two edited beagles are healthy at nearly two years old.
In flatworms, Stanford researchers found ‘ruptoblasts’ that self-destruct within seconds to destroy nearby bacteria — a defense mechanism never seen before.
The drugmaker added $1 billion to its savings target and raised its 2026 revenue outlook, even as COVID sales collapse and several cancer drugs slip.
University of Pennsylvania researchers found a gum made from lablab beans sharply reduced HPV in oral samples — an early, lab-only step toward preventing HPV-linked cancers.